Mechanism of Action
Beta-Hairpin Antimicrobial Action
Like tachyplesin, polyphemusin I uses its beta-hairpin structure stabilized by two disulfide bonds to interact with bacterial outer membranes. LPS binding triggers conformational changes that allow insertion into the inner membrane, forming pores and causing rapid cell death. The arginine-rich structure provides electrostatic targeting to anionic lipopolysaccharide headgroups.
CXCR4 Antagonism and T22 Lineage
Polyphemusin II analogs, particularly T22, were found to potently block CXCR4 with IC50 values in the low nanomolar range. The beta-hairpin scaffold mimics the CXCR4 natural ligand SDF-1/CXCL12 in terms of presenting basic residues in a spatially defined arrangement. The pharmacological insights from polyphemusin/T22 structure-activity studies directly informed the development of AMD3100, which retains the core cyclam ring that positions basic nitrogen atoms analogously to the polyphemusin beta-hairpin arginines.
Research Summary
CXCR4 Antagonist Development
Preclinical (led to FDA-approved AMD3100)The polyphemusin T22 analog inhibits CXCR4-tropic HIV replication at nanomolar concentrations without T-cell toxicity. Further optimization of T22 led to T140, TN14003, and ultimately the series of polyphemusin analogs that informed AMD3100 chemistry. AMD3100 (plerixafor/Mozobil) is FDA-approved for hematopoietic stem cell mobilization, representing the clinical translation of polyphemusin pharmacology even though the peptide itself is not the approved drug.
Cancer Metastasis
PreclinicalCXCR4 is overexpressed in multiple cancers and mediates metastasis to CXCL12-rich bone marrow and lymph nodes. Polyphemusin-derived T22 and its analogs block cancer cell migration along CXCL12 gradients in vitro. Nanoparticle delivery of T22-conjugated systems is being developed to selectively target CXCR4-overexpressing tumor cells for drug delivery.
Calculate your Polyphemusin dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Antimicrobial (in vitro) | 1-5 uM MIC | Single exposure | Direct application |
| CXCR4 antagonism (T22) | 1-100 nM | Continuous exposure | Research only |
AMD3100 (plerixafor) is the FDA-approved CXCR4 antagonist in this lineage; polyphemusin itself is not approved for human use.
Interactions
Safety Profile
Polyphemusin I shows significant hemolytic activity at higher concentrations. T22 and optimized analogs have improved selectivity. CXCR4 antagonism may affect normal hematopoiesis and immune cell trafficking, requiring careful dosing in clinical applications. No human clinical data for polyphemusin peptides themselves.
References
- [1]Miyata T, et al. (1989). Antimicrobial peptides, isolated from horseshoe crab hemocytes, tachyplesin II, and polyphemusins I and II: chemical structures and biological activity. J Biochem, 106(4), 663-668.
- [2]Tamamura H, et al. (2003). Pharmacophore identification of a chemokine receptor (CXCR4) antagonist, T22. Biochemistry, 42(11), 3350-3356.